Free Trial
Lachlan Hanbury-Brown

Lachlan Hanbury-Brown Analyst Performance

Biotech Equity Research Analyst at William Blair

Lachlan Hanbury-Brown is a stock analyst at William Blair focused in the healthcare sector, covering 12 publicly traded companies. Over the past year, Lachlan Hanbury-Brown has issued 4 stock ratings, including and buy recommendations. While full access to Lachlan Hanbury-Brown's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Lachlan Hanbury-Brown's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
16 Last 2 Years
Buy Recommendations
87.50% 14 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy31.3%5 ratings
Buy56.3%9 ratings
Hold12.5%2 ratings
Sell0.0%0 ratings

Out of 16 total stock ratings issued by Lachlan Hanbury-Brown at William Blair, the majority (56.3%) have been Buy recommendations, followed by 31.3% Strong Buy and 12.5% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
91.7% of companies on NASDAQ
11 companies
OTCMKTS
8.3% of companies on OTCMKTS
1 company

Lachlan Hanbury-Brown, an analyst at William Blair, currently covers 12 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
11 companies
91.7%
Finance
1 company
8.3%

Lachlan Hanbury-Brown of William Blair specializes in stock coverage within the Healthcare sector, with additional focus on Finance companies.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
6 companies
50.0%
BIOTECHNOLOGY
5 companies
41.7%
FINANCIAL SERVICES
1 company
8.3%

Lachlan Hanbury-Brown's Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Surrozen, Inc. stock logo
SRZN
Surrozen
8/20/2026Initiated Coverage$24.01$51.00Outperform
Surrozen, Inc. stock logo
SRZN
Surrozen
8/20/2026Initiated Coverage$23.50$51.00Outperform
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
3/23/2026Initiated Coverage$7.10Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
12/3/2025Initiated Coverage$30.43Outperform
Harrow, Inc. stock logo
HROW
Harrow
6/10/2025Initiated Coverage$30.15Outperform
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
4/8/2025Initiated Coverage$6.30Outperform
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3/3/2025Reiterated Rating$10.33Outperform
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2/21/2025Reiterated Rating$11.24Outperform
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
11/15/2024Reiterated Rating$0.10Market Perform